S.A. Mason LLC Cuts Stake in Illumina, Inc. (NASDAQ:ILMN)

S.A. Mason LLC reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 29.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,250 shares of the life sciences company’s stock after selling 520 shares during the quarter. S.A. Mason LLC’s holdings in Illumina were worth $172,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. abrdn plc lifted its stake in shares of Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after buying an additional 299,827 shares during the period. Norges Bank acquired a new stake in shares of Illumina during the fourth quarter worth $264,636,000. International Assets Investment Management LLC lifted its stake in shares of Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after buying an additional 32,672 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Illumina by 49.0% during the fourth quarter. BNP Paribas Financial Markets now owns 275,762 shares of the life sciences company’s stock worth $38,397,000 after buying an additional 90,634 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Illumina by 5.9% during the fourth quarter. Victory Capital Management Inc. now owns 122,743 shares of the life sciences company’s stock worth $17,091,000 after buying an additional 6,827 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Barclays lifted their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Robert W. Baird lifted their price objective on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. TD Cowen lowered their price objective on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Royal Bank of Canada restated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Finally, Jefferies Financial Group initiated coverage on shares of Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price for the company. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $158.14.

Illumina Trading Up 0.7 %

Shares of ILMN stock traded up $0.75 on Thursday, reaching $106.43. 258,199 shares of the company were exchanged, compared to its average volume of 2,164,825. The business has a 50-day moving average price of $112.34 and a 200 day moving average price of $127.64. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $195.64.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. On average, research analysts forecast that Illumina, Inc. will post 0.98 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.